Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

EXCEL Sub-Study: The Site of the Left Main Coronary Artery Lesion Does Not Alter History

The EXCEL study, originally presented at TCT 2016 and published simultaneously in the New England Journal of Medicine (NEJM), showed that angioplasty and surgery in patients with left main coronary artery disease have similar rates of mortality, infarction, and stroke at 3 years.

perforación coronaria en angioplastiaThis sub-study, recently published in J Am Coll Cardiol Intv, adds that the site of the left main coronary artery lesion (ostial, shaft, or bifurcation lesion) does not alter the outcomes of the overall study. An important detail: the EXCEL trial (unlike almost all studies carried out in these last years) did not include revascularization in its primary endpoint; only death, infarction, and stroke.

 

Revascularization was analyzed as a secondary endpoint and offered no surprises: clinically-driven revascularization was more frequent in patients with distal lesions, but it was similar to surgery in patients with ostial or shaft lesions.


Read also: Post-Dilation in Valve-in-Valve Implantation Offers Hemodynamic Improvement.


About 84.2% (n = 1559) of patients experienced distal bifurcation lesions vs. 15.8% (n = 293) who presented isolated ostial or shaft lesions.

 

At 3 years, there were no significant differences between angioplasty and surgery in the composite primary endpoint of death, infarction, and stroke regarding both the distal segment (15.6% vs. 14.9%; odds ratio [OR]: 1.08; 95% confidence interval [CI]: 0.81 to 1.42; p = 0.61) and isolated ostial or shaft lesions (12.4% vs. 13.5 %; OR: 0.90; 95% CI: 0.45 to 1.81; p = 0.77) (p for interaction = 0.65).


Read also: Noradrenaline seems superior to adrenaline in patients with cardiogenic shock.


Ischemia-driven revascularization was more frequent in patients who underwent angioplasty when the lesion was located in the distal segment of the left main coronary artery (13.0% vs. 7.2%; OR: 2.00; p = 0.0001), but there was no difference between both revascularization strategies in patients with ostial or shaft lesions (9.7% vs. 8.4%; OR: 1.18; p = 0.68).

 

Conclusion

In the EXCEL study, angioplasty and surgery were comparable in terms of death, infarction, or stroke at three years in patients with left main coronary artery lesions, including those with distal bifurcation lesions. Repeat revascularization during follow-up was more frequent after angioplasty in patients with distal lesions, but not in patients with shaft or ostial lesions.

 

Original title: Outcomes After Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting According to Lesion Site. Results from the EXCEL Trial.

Reference: Anthony H. Gershlick et al. J Am Coll Cardiol Intv 2018;11:1224-33.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | Are bioresorbable stents making a comeback? Five-year results of FUTURE-II with Firesorb

The first bioresorbable coronary scaffolds generated great expectations because of their potential to restore vascular physiology after device resorption. However, early studies such as...

EuroPCR 2026 | Coronary bioadaptor: fewer events regardless of IVUS or FFR guidance

Despite the increasing use of intracoronary imaging and physiology, stent-related events continue to occur at an annual rate of approximately 2–3% beyond the first...

EuroPCR 2026 | Is localized anticoagulation the next step for coronary stents?

The DESyne BDS Plus stent was developed as a thin-strut, bioabsorbable polymer drug-eluting stent that combines sirolimus release with two anticoagulant agents (rivaroxaban and...

EuroPCR 2026 | Restoring vascular physiology: 4-year results of the BIOADAPTOR-RCT

Despite advances in drug-eluting stents, device-related events continue to increase beyond the first year after angioplasty. In this context, the DynamX system emerged as...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

EuroPCR 2026 | Are bioresorbable stents making a comeback? Five-year results of FUTURE-II with Firesorb

The first bioresorbable coronary scaffolds generated great expectations because of their potential to restore vascular physiology after device resorption. However, early studies such as...

EuroPCR 2026 | Coronary bioadaptor: fewer events regardless of IVUS or FFR guidance

Despite the increasing use of intracoronary imaging and physiology, stent-related events continue to occur at an annual rate of approximately 2–3% beyond the first...